{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:01:37Z","timestamp":1784635297913,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) is a prevalent autoimmune disease affecting up to a quarter million Americans. Lupus nephritis (LN) is an immune complex glomerulonephritis that occurs when circulating immune complexes deposit in the kidney and is a common sequela of SLE. LN serves as a marker of disease severity and contributes significantly to mortality in SLE. Despite growing access to novel therapies, the disease burden remains high, and the gap between real-life challenges and clinical trial success persists. Our study is an effort to bridge the gap by examining factors such as diverse choice of immunosuppression, socioeconomic constraints, and adherence outside the carefully calibrated environment of clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of patients with biopsy proven LN to evaluate prognostic factors and treatment related complications at a tertiary hospital with patients selected from biopsy records obtained from January 2015 through December 2023. A total of 66 patients met inclusion criteria and were included in the final analysis of the cohort. Patients with findings other than confirmed LN and kidney transplant recipients were excluded. Longitudinal data were collected at 6 months, 12 months, 2 years, and 5 years after biopsy, and response to treatment was defined using Kidney Disease Improving Global Outcomes (KDIGO) 2024 clinical practice guidelines for LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 163 kidney biopsy reports reviewed from January 2015 through December 2023, 66 were confirmed as LN and included in the analysis. The median age at biopsy was 35 years, 76% were women, and 62% were African American. At 6 months, 50% of Class I and II LN, 49% of Class III, IV, III + V and IV + V LN, and 83% of Class V LN had no response to treatment, without significant differences between classes or in terms of partial vs. complete response. At 12 months, 55% of Class I and II, 50% of Class III, IV, III + V, and IV + V, and 87% of Class V LN had no response to treatment, with a significant difference (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04) between classes in terms of rate of response, but not in terms of partial vs. complete response. Notable complications were advancement to ESRD in 11 patients (17%), infections that required hospital admission in 27 patients (41%), and death in 9 patients (14%) in the study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study provides practical and real-world data on management of LN. In patients with SLE, LN is associated with significant morbidity and mortality. Management continues to pose a unique challenge despite developing therapies. Sustained remission is often dependent on a complex interplay of individualized care, patient adherence, and socioeconomic factors. There is a need for increased awareness of LN as early biopsy, prompt initiation and continuation of treatment positively impacts outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1868000","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:10:25Z","timestamp":1784632225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the trial: a single-center retrospective review of real-world lupus nephritis management and outcomes"],"prefix":"10.3389","volume":"13","author":[{"given":"Dylan","family":"Clapp","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugdha","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Geisinger College of Health Sciences","place":["Scranton, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Health Informatics, and Data Sciences, University of Cincinnati College of Medicine","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Cincinnati College of Medicine","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.41632","article-title":"Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries","volume":"73","author":"Izmirly","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber","year":"2021","journal-title":"Nat Rev Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/rheumatology\/kep012","article-title":"Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort","volume":"48","author":"Danila","year":"2009","journal-title":"Rheumatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"849684","DOI":"10.1155\/2012\/849684","article-title":"Lupus nephritis: an overview of recent findings","volume":"2012","author":"de Zubiria Salgado","year":"2012","journal-title":"Autoimmune Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers."},{"key":"B9","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 Clinical Practice Guideline for the management of lupus nephritis","volume":"105","author":"Kidney","year":"2024","journal-title":"Kidney Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population","volume":"81","author":"Yu","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/09612033221081531","article-title":"Clinical characteristics and long-term outcomes in patients with mixed Class III\/IV + V and pure proliferative lupus nephritis: a single-center experience","volume":"31","author":"Ahn","year":"2022","journal-title":"Lupus."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/rheumatology\/keae236","article-title":"Risk of chronic kidney disease in 260 patients with lupus nephritis: analysis of a nationwide multicentre cohort with up to 35 years of follow-up","volume":"64","author":"Farinha","year":"2025","journal-title":"Rheumatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1136\/annrheumdis-2017-212732","article-title":"Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis","volume":"77","author":"Moroni","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e001264","DOI":"10.1136\/lupus-2024-001264","article-title":"Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort","volume":"11","author":"Urowitz","year":"2024","journal-title":"Lupus Sci Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/09612033261415978","article-title":"Predictors of long-term renal survival and mortality in patients with proliferative and membranous lupus nephritis","volume":"35","author":"Shin","year":"2026","journal-title":"Lupus."},{"key":"B17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1191\/0961203305lu2238oa","article-title":"Factors associated with poor outcomes in patients with lupus nephritis","volume":"14","author":"Contreras","year":"2005","journal-title":"Lupus."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e20240118","DOI":"10.1590\/2175-8239-JBN-2024-0118en","article-title":"Renal outcomes in the long-term follow-up of lupus nephritis","volume":"47","author":"Polycarpo","year":"2025","journal-title":"J Bras Nefrol."},{"key":"B19","first-page":"1563","article-title":"Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure","volume":"33","author":"Faurschou","year":"2006","journal-title":"J Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e003158","DOI":"10.1136\/rmdopen-2023-003158","article-title":"Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?","volume":"9","author":"Panagiotopoulos","year":"2023","journal-title":"RMD Open."},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.18553\/jmcp.2022.21496","article-title":"Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States","volume":"29","author":"Dall'Era","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant."},{"key":"B23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/0961203314567751","article-title":"Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre","volume":"24","author":"Mahmoud","year":"2015","journal-title":"Lupus."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/keae381","article-title":"Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes","volume":"64","author":"Panagiotopoulos","year":"2025","journal-title":"Rheumatology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"i22","DOI":"10.1093\/rheumatology\/keac678","article-title":"Dilemma of immunosuppression and infection risk in systemic lupus erythematosus","volume":"62","author":"He","year":"2023","journal-title":"Rheumatology."},{"key":"B26","unstructured":"Real-world immunosuppressant treatment patterns in lupus nephritis: a retrospective claims database analysis in the United States [Abstract]\n          \n          77\n          \n            \n              Patel\n              A\n            \n            \n              Miller\n              A\n            \n            \n              Lindsay\n              L\n            \n            \n              Sheinson\n              D\n            \n            \n              Xia\n              Z\n            \n            \n              Pendergraft\n              W\n            \n          \n          Arthritis Rheumatol\n          \n          2025"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:10:26Z","timestamp":1784632226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1868000"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1868000","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1868000"}}